Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, ...

Ochsner Health is expanding its partnership with The University of Texas MD Anderson Cancer Center to Slidell Memorial Hospital, bringing one of the nation’s most advanced cancer treatment programs to ...

At The University of Texas MD Anderson Cancer Center, our mission has always been clear: to end cancer. Achieving this goal requires more than just groundbreaking research and exceptional patient care ...

Researchers at The University of Texas MD Anderson Cancer Center have identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from ...

Naval Daver, MD, who leads a number of acute myeloid leukemia (AML) research trials at MD Anderson Cancer Center in Houston, looks forward to a future where the treatment for AML is truly personalized ...

Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according ...

The University of Texas MD Anderson Cancer Center in Houston is partnering with SOPHiA GENETICS to advance the use of artificial intelligence in cancer diagnostics and research. Through the ...

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and ...